Bone marrow transplantation for autoimmune diseases

Current Opinion in Oncology

Volumn 11, Issue 2, 1999, Pages 83-86

  Brodsky, Robert A ^a   Smith, B Douglas ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; PREDNISONE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ASEPTIC NECROSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CATARACT; DIABETES MELLITUS; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPATHOGENESIS; LIFE EXPECTANCY; MORBIDITY; MORTALITY; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; HUMANS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032992540     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199903000-00002     Document Type: Short Survey

References (27)

1. Ikehara S: Bone marrow transplantation for autoimmune diseases. Acta Haematol 1998, 99:116-132.
2. Burt RK: BMT for severe autoimmune diseases: An idea whose time has come. Oncology 1997, 11:1001-1017.
3. Snowden JA, Brooks PM, Biggs JC: Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol 1997, 99:9-22. Outstanding review that thoroughly covers autoimmune animal models and the early results of hematopoietic stem cell transplantation in humans.
4. Pestronk A, Drachman DB, Adams RN: Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle Nerve 1982, 79-84.
5. Karussis DM, Slavin S, Ben-Nun A, Ovadia H, Vourka-Karussis U, Lehmann D, et al.: Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmunol 1992, 39:201-210.
6. Snowden JA, Kearney P, Kearney A, Cooley HM, Grigg A, Jacobs P, et al.: Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum 1998, 41:453-459. Confirms the long-term (greater than 10 years follow-up) curative potential of rheumatoid arthritis following allogeneic bone marrow transplantation.
7. Lopez-Cubero SO, Sullivan KM, McDonald GB: Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 1998, 114:433-440. Demonstration that Crohn's disease may be cured following allogeneic bone marrow transplantation.
8. McAllister LD, Beatty PG, Rose J: Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 1997, 19:395-397.
9. Ward MM, Pyun E, Studendski S: Long-term survival in systemic lupus erythematosus. Arthritis Rheum 1995, 38:274-283.
10. Artlett CM, Smith JB, Jimenez SA: Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998, 338:1186-1191. Provocative paper demonstrating that fetal antimaternal graft-versus-host reactions may be important in the pathogenesis of systemic sclerosis.
11. Conrad G, Weissmahr RN, Böni J, Arcari R, Schüpbach J, Mach B: A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell 1997, 90:303-313.
12. Pestronk A, Drachman DB, Teoh R, Adams RN: Combined short-term immunotherapy for experimental autoimmune myasthenia gravis. Ann Neural 1983, 14:235-241.
13. Euler HH, Marmont AM, Bacigalupo A, Fastenrath S, Dreger P, Hoffknecht M, et al.: Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996, 88:3621-3625.
14. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, Tsompanakou A: Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997, 20:631-638. First relatively large study of autologous stem cell transplantation for multiple sclerosis. The report demonstrates the feasibility of stem cell transplantation in this population. The preliminary results are encouraging, but follow-up is too short to show if the benefits counterbalance the cost and toxicity.
15. Burt RK, Traynor AE, Cohen B, Karlin KH, Davis FA, Stefoski D, et al.: T Cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998, 21;537-541. Small study documenting modest clinical improvement in three multiple sclerosis patients following T cell-depleted autologous stem cell transplantation. The paper demonstrates the safety of this approach in patients with late-stage disease.
16. Lim SH, Kell J, Al-Sabah A, Bashi W, Bailey-Wood R: Peripheral blood stem-cell transplantation for refractory autoimmune thrombocytopenic purpura. Lancet 1997, 349:475.
17. Joske DJL: Autologous bone-marrow transplantation for rheumatoid arthritis. Lancet 1997, 350:337-338.
18. Skoda RC, Tichelli A, Tyndall A, Hoffman T, Gillessen S, Gratwohl A: Autologous peripheral blood stem cell transplantation in a patient with chronic autoimmune thrombocytopenia. Br J Haematol 1997, 99:56-57.
19. Passweg JR, Socie G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM, et al.: Bone marrow transplantation for severe aplastic anemia: Has outcome improved? Blood 1997, 90:858-864.
20. May WS, Sensenbrenner LL, Burns WH, Ambinder R, Carroll MP, Jones RJ, et al.: BMT for severe aplastic anemia using cyclosporin. Bone Marrow Transplant 1993, 11:459-464.
21. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, et al.: Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994, 84:941-949.
22. Sensenbrenner LL, Steele AA, Santos GW: Recovery of hematologic competence without engraftment following attempted bone marrow transplantation for aplastic anemia: Report of a case with diffusion chamber studies. Exp Hematol 1977, 77:51-58.
23. Thomas ED, Storb R, Giblett ER, Longpre B, Weiden PL, Fefer A, et al.: Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol 1976, 4:97-102.
24. Brodsky RA, Sensenbrenner LL, Jones RJ: Complete remission in acquired severe aplastic anemia following high-dose cyclophosphamide. Blood 1996, 87:491-494.
25. Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, Hilton J: Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990, 75:1947-1950.
26. Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, et al.: Assessment of aldehyde dehydrogenase in viable cells. Blood 1995, 85:2742-2746.
27. Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, et al.: Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease. Ann Intern Med 1998, 129:1031-1035. Demonstrates that high-dose cyclophosphamide without stem cell rescue can induce durable complete remissions in a subset of patients with refractory severe autoimmune diseases. Immunoablative high-dose cyclophosphamide is less toxic and less expensive than stem cell transplantation and circumvents the potential problem of reinfusing autoreactive lymphocytes.